caa a22 4500 44588777X CHVBK 20180317145604.0 cr unu---uuuuu 170323e20110101xx s 000 0 eng 10.1007/s00535-010-0291-8 doi (NATIONALLICENCE)springer-10.1007/s00535-010-0291-8 Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease [Elektronische Daten] [Hyohun Park, Toshihide Shima, Kanji Yamaguchi, Hironori Mitsuyoshi, Masahito Minami, Kohichiroh Yasui, Yoshito Itoh, Toshikazu Yoshikawa, Michiaki Fukui, Goji Hasegawa, Naoto Nakamura, Mitsuhiro Ohta, Hiroshi Obayashi, Takeshi Okanoue] Background: Hyperlipidemia, insulin resistance, and oxidative stress can heavily contribute to the initiation and progression of nonalcoholic fatty liver disease (NAFLD). Currently, there is no established treatment for this disease. Recently, several studies have shown that ezetimibe (EZ), a lipid-lowering drug, attenuates liver steatosis in an experimental NAFLD model. This study was designed to assess the efficacy of long-term EZ monotherapy in patients with NAFLD. Methods: A total of 45 patients with newly diagnosed liver biopsy-proven NAFLD were treated with EZ (10mg/day) for 24months. NAFLD-related biochemical parameters, imaging by computerized tomography, and liver biopsy were studied before and after treatment. Results: Ezetimibe therapy significantly improved NAFLD-related metabolic parameters including visceral fat area, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-R), triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-Ch), oxidative-LDL, the net electronegative charge modified-LDL, profiles of lipoprotein particle size and fatty acids component, and estimated desaturase activity. EZ therapy also significantly lowered serum alanine aminotransferase and high-sensitivity C-reactive protein levels, whereas no significant changes were found in serum type IV collagen 7S, adiponectin, leptin, and resistin levels. Histological features of steatosis grade (P=0.0003), necroinflammatory grade (P=0.0456), ballooning score (P=0.0253), and NAFLD activity score (NAS) (P=0.0007) were significantly improved from baseline. However, the fibrosis stage was not significantly (P=0.6547) changed. Conclusion: The results in this study suggest that the long-term EZ therapy can lead to improvement in metabolic, biochemical, and histological abnormalities of NAFLD. Therefore, EZ may be a promising agent for treatment of NAFLD. Springer, 2010 Ezetimibe nationallicence NAFLD nationallicence Insulin resistance nationallicence Lipid metabolism nationallicence Fatty acid metabolism nationallicence Park Hyohun Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, 1-2 Kawazono-cho, 564-0013, Suita, Osaka, Japan aut Shima Toshihide Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, 1-2 Kawazono-cho, 564-0013, Suita, Osaka, Japan aut Yamaguchi Kanji Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut Mitsuyoshi Hironori Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut Minami Masahito Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut Yasui Kohichiroh Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut Itoh Yoshito Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut Yoshikawa Toshikazu Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut Fukui Michiaki Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut Hasegawa Goji Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut Nakamura Naoto Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut Ohta Mitsuhiro Department of Medical Biochemistry, Kobe Pharmaceutical University, Kobe, Japan aut Obayashi Hiroshi Department of Molecular Biochemistry, Institute of Bio-Response Informatics, Kyoto, Japan aut Okanoue Takeshi Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, 1-2 Kawazono-cho, 564-0013, Suita, Osaka, Japan aut Journal of Gastroenterology Springer Japan 46/1(2011-01-01), 101-107 0944-1174 46:1<101 2011 46 535 https://doi.org/10.1007/s00535-010-0291-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00535-010-0291-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Park Hyohun Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, 1-2 Kawazono-cho, 564-0013, Suita, Osaka, Japan aut NATIONALLICENCE 700 1- Shima Toshihide Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, 1-2 Kawazono-cho, 564-0013, Suita, Osaka, Japan aut NATIONALLICENCE 700 1- Yamaguchi Kanji Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut NATIONALLICENCE 700 1- Mitsuyoshi Hironori Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut NATIONALLICENCE 700 1- Minami Masahito Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut NATIONALLICENCE 700 1- Yasui Kohichiroh Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut NATIONALLICENCE 700 1- Itoh Yoshito Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut NATIONALLICENCE 700 1- Yoshikawa Toshikazu Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut NATIONALLICENCE 700 1- Fukui Michiaki Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut NATIONALLICENCE 700 1- Hasegawa Goji Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut NATIONALLICENCE 700 1- Nakamura Naoto Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan aut NATIONALLICENCE 700 1- Ohta Mitsuhiro Department of Medical Biochemistry, Kobe Pharmaceutical University, Kobe, Japan aut NATIONALLICENCE 700 1- Obayashi Hiroshi Department of Molecular Biochemistry, Institute of Bio-Response Informatics, Kyoto, Japan aut NATIONALLICENCE 700 1- Okanoue Takeshi Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, 1-2 Kawazono-cho, 564-0013, Suita, Osaka, Japan aut NATIONALLICENCE 773 0- Journal of Gastroenterology Springer Japan 46/1(2011-01-01), 101-107 0944-1174 46:1<101 2011 46 535 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer